SageGuard Financial Group LLC Invests $1.50 Million in Merck & Co., Inc. $MRK

SageGuard Financial Group LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,280 shares of the company’s stock, valued at approximately $1,503,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Darwin Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the period. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. during the third quarter worth $31,000. Wealth Watch Advisors INC acquired a new position in shares of Merck & Co., Inc. during the third quarter worth $34,000. Finally, Deane Retirement Strategies Inc. acquired a new position in shares of Merck & Co., Inc. during the third quarter worth $35,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Trading Down 1.6%

MRK opened at $117.15 on Tuesday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company has a fifty day moving average of $119.11 and a 200-day moving average of $106.32. The stock has a market cap of $289.34 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 2.39 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period in the prior year, the company posted $1.72 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 4.93 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were given a dividend of $0.85 per share. The ex-dividend date was Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the sale, the insider owned 21,197 shares in the company, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 320,176 shares of company stock worth $38,281,735 over the last quarter. 0.09% of the stock is owned by company insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted priority review for two supplemental BLAs for KEYTRUDA (and KEYTRUDA QLEX) in combination with Padcev for cisplatin-eligible muscle?invasive bladder cancer — a regulatory acceleration that can expand KEYTRUDA’s label and near?term revenue potential. FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX with Padcev
• Positive Sentiment: European Union approves ENFLONSIA (RSV monoclonal antibody) to protect infants during their first RSV season — adds a near?term revenue driver in prophylaxis and diversifies pediatric portfolio. Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
• Neutral Sentiment: Market commentary and valuation pieces highlight Merck’s recent outperformance (one?year gains) and short?term pullbacks — useful context for positioning but not new company fundamentals. 3 Reasons We Love Merck (MRK)
• Negative Sentiment: Merck and Eisai said the Phase 3 LITESPARK?012 combination regimens for certain first?line advanced renal cell carcinoma failed to meet key primary endpoints — a material pipeline setback for MRK’s kidney?cancer franchise and a driver of today’s downside pressure. Merck-Eisai’s combination cancer therapy fails to meet main goals of late-stage study
• Negative Sentiment: Merck/Eisai corporate update on the Phase 3 LITESPARK?012 trial acknowledges the miss and signals additional data review; this will prompt investor focus on secondary endpoints, label prospects, and any impact to long?term guidance. Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. TD Cowen raised their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Finally, Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $128.47.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.